Simona Di Martino

Simona Di Martino

Auto-generated profile, based on publicly available information

Simona Di Martino

Medicinal Chemistry Group, Fondazione Ri.MED, Palermo, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

8 December 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SCSamantha Caputo
Samantha Caputo
SMSimona Di Martino
Simona Di Martino
VCVincenzo Cilibrasi
Vincenzo Cilibrasi
PTPiero Tardia
Piero Tardia
MMMarco Mazzonna
Marco Mazzonna
RSRita Scarpelli
Rita Scarpelli
Acid ceramidase (AC) is a cysteine hydrolase that plays a crucial role in the metabolism of lysosomal ceramides, important members of the sphingolipid family, a diversified class of bioactive molecules that mediate many biological processes ranging from cell structural integrity, signaling, and cell proliferation to cell death. In the effort to expand the structural diversity of the existing collection of AC inhibitors, a novel class of substituted oxazol-2-one-3-carboxamides were designed and synthesized. Herein, we present the chemical optimization of our initial hits, 2-oxo-4-phenyl-N-(4-phenylbutyl)oxazole-3-carboxamide 8a and 2-oxo-5-phenyl-N-(4-phenylbutyl)oxazole-3-carboxamide 12a, which resulted in the identification of 5-[4-fluoro-2-(1-methyl-4-piperidyl)phenyl]-2-oxo-N-pentyl-oxazole-3-carboxamide 32b as a potent AC inhibitor with optimal physicochemical and metabolic properties, showing target engagement in human neuroblastoma SH-SY5Y cells and a desirable pharmacokinetic profile in mice, following intravenous and oral administration. 32b enriches the arsenal of promising lead compounds that may therefore act as useful pharmacological tools for investigating the potential therapeutic effects of AC inhibition in relevant sphingolipid-mediated disorders.

16 March 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SMSimona Di Martino
Simona Di Martino
PTPiero Tardia
Piero Tardia
VCVincenzo Cilibrasi
Vincenzo Cilibrasi
SCSamantha Caputo
Samantha Caputo
MMMarco Mazzonna
Marco Mazzonna
RSRita Scarpelli
Rita Scarpelli
Sphingolipids (SphLs) are a diverse class of molecules that are regulated by a complex network of enzymatic pathways. A disturbance in these pathways leads to lipid accumulation and initiation of several SphL- related disorders. Acid ceramidase is one of the key enzymes that regulate the metabolism of ceramides and glycosphingolipids, which are important members of the SphL family. Herein, we describe the lead optimization studies of benzoxazolone carboxamides resulting in piperidine 22m, where we demonstrated target engagement in two animal models of neuropathic lysosomal storage diseases (LSDs), Gaucher’s and Krabbe’s diseases. After daily intraperitoneal administration at 90 mg Kg-1, 22m significantly reduced the brain levels of the toxic lipids glucosylsphingosine (GluSph) in 4L;C* mice and galactosylsphingosine (GalSph) in Twitcher mice. We believe that 22m is a lead molecule that can be further developed for the correction of severe neurological LSDs, where GluSph or GalSph play a significant role in disease pathogenesis.

21 March 2025 in Topics in Current Chemistry
Verified
Journal Article
Closed access
PDF file
SMSimona Di Martino
Simona Di Martino
Pietro AmicoPietro Amico
Pietro Amico
MRMaria De Rosa
Maria De Rosa


22 October 2026 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
EPElvira Passalacqua
Elvira Passalacqua
GBGiuseppe Barberi
Giuseppe Barberi
Pietro AmicoPietro Amico
Pietro Amico
SMSimona Di Martino
Simona Di Martino
MRMaria De Rosa
Maria De Rosa
PDCs include a payload conjugated to a suitable peptide, often via a cleavable linker, and were developed to address BBB limitations and hit specific sites in the brain, increasing drugs' therapeutic efficacy, and reducing off-target toxicity.